DS
LAB icon

David Shaw’s Standard BioTools LAB Stock Holding History

David Shaw’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$588K – 4252
2014
Q2 		$588K Sell
20,000
-14,600
-42% -$468K ﹤0.01% 3396
2014
Q1 		$1.52M Buy
+34,600
New +$1.52M ﹤0.01% 2650

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

David Shaw's LAB Position: Q2 2026 in Review

David Shaw increased its Standard BioTools (LAB) stake by 1,315% in Q2 2026, buying an estimated $2.47M and bringing the position to 2,818,026 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

David Shaw first reported a position in LAB in Q2 2013 and has held it in 35 quarters since. The position peaked at $12.4M in Q1 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • David Shaw held 2,818,026 shares of Standard BioTools worth $2.32M as of Q2 2026.
  • David Shaw bought 2,618,942 Standard BioTools shares in Q2 2026, an estimated $2.47M.
  • Standard BioTools made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3074 holding.
  • David Shaw first reported a position in Standard BioTools in Q2 2013 and has held it in 35 quarters since.
  • David Shaw's Standard BioTools position peaked at $12.4M in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.